Metal Containing, E.g., Chromoproteins, Ferritin, Ferredoxins, Etc. Patents (Class 530/400)
  • Publication number: 20120053072
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble Advanced glycosylation end product-specific receptor, Bactericidal permeability-increasing protein, Interleukin 12, Fibroblast growth factor 23, and Intestinal fatty acid-binding protein as diagnostic and prognostic biomarkers in renal injuries.
    Type: Application
    Filed: February 5, 2010
    Publication date: March 1, 2012
    Applicant: ASTUTE MEDICAL, INC.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura
  • Publication number: 20120052513
    Abstract: The present technology relates gold sub-nanoclusters comprising a gold core and one or more thiolates bound to the gold core, wherein the gold core consists essentially of 23 gold atoms. Methods of preparing and using such sub-nanoclusters are also provided.
    Type: Application
    Filed: August 24, 2010
    Publication date: March 1, 2012
    Inventors: Pradeep THALAPPIL, Madathumpady Abubaker Habeeb Muhammed
  • Publication number: 20120040378
    Abstract: Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.
    Type: Application
    Filed: August 9, 2011
    Publication date: February 16, 2012
    Applicant: RANDOX LABORATORIES LIMITED
    Inventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
  • Publication number: 20120027742
    Abstract: We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.
    Type: Application
    Filed: October 1, 2008
    Publication date: February 2, 2012
    Applicant: Columbia University in the City of New York
    Inventors: Jahar Bhattacharya, Sadiqa K. Quadri, Shonit Das
  • Publication number: 20120021450
    Abstract: In certain aspects the present invention provides methods and compositions related to contrast agents for magnetic resonance imaging. In certain variations, contrast agents provided herein are generated in situ via genetic instructions and become potent upon sequestering available metal atoms. Exemplary contrast agents include metal-binding proteins.
    Type: Application
    Filed: July 18, 2011
    Publication date: January 26, 2012
    Applicant: CARNEGIE MELLON UNIVERSITY
    Inventors: Eric T. Ahrens, Clinton S. Robison
  • Publication number: 20120009669
    Abstract: A bifunctional compound with a monosaccharide and a N2S2 ligand, and more particularly, a bifunctional compound with a N2S2 ligand and aminohexylacetyl galactosamine (ah-GalNAc4) is provided. A method for preparing the bifunctional compound with a monosaccharide and a N2S2 ligand is also provided, including activating a carboxyl group in an organic ligand, reacting the activated carboxyl group with a galactopyranoside through amidation, and then hydrolyzing. The bifunctional compound of the present invention is widely useful in nuclear medicine for preparation of liver imaging agents for assisting in correct diagnosis of diseases.
    Type: Application
    Filed: April 15, 2011
    Publication date: January 12, 2012
    Applicant: Institute of Nuclear Energy Research Atomic Energy Council, Executive Yuan
    Inventors: SHOW-WEN LIU, CHENG-HSIEN LIN, YU CHANG, CHENG-FANG HSU, TSYH-LANG LIN
  • Publication number: 20110318827
    Abstract: The present invention relates to a peptide tag which can be used to bind a Technetium (Tc) or Rhenium (Re) radionuclide to a protein of interest which comprises the peptide tag and allows the imaging of such a tagged protein. In particular the present invention relates to a peptide tag which chelates a Tc or Re atom but which does not comprise a Cysteine residue.
    Type: Application
    Filed: December 28, 2009
    Publication date: December 29, 2011
    Inventors: Loïc Le Clainche, Alain Lecoq, Sophie Zinn-Justin, Robert Thai, Michel Masella, Philippe Cuniasse
  • Publication number: 20110318275
    Abstract: The present invention relates to a biocompatible contrast agent and a method of its preparation. More particularly, the present invention relates to a multifunctional contrast agent manufactured by prepairing a novel polysuccinimide-based polymer by introducing an alkanolamine group to the main group of the polysuccinimide in addition to a biocompatible hydrophilic group, which improves bioavailability, and a hydrophobic group, which enables to maintain the form of stable nanoparticles during the formation of nano particles for a long period of time and to encapsulate a hydrophobic anticancer agent.
    Type: Application
    Filed: September 28, 2009
    Publication date: December 29, 2011
    Applicants: KOREA UNITED PHARM. INC., KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Sun Hang Cho, Byung Cheol Shin, Soon Hong Yuk, Ha Soo Seong, Byung Jin Kim, Hyo Jeong Kim, Youn Woong Choi, Byung Gu Min, Dae Chul Ha
  • Publication number: 20110311505
    Abstract: This invention is related to preparation of photosensitive ruthenium based aminoacid monomers and oligomers, aminoacid monomer-protein cross-linking using photo sensitat ion and conjugation on micro and nano-structures by ruthenium-chelate based monomers. Its vast range biotechnolgy applications of multifunctional, biocompatible, stabilE and specific micro and nanobio-conjugates, which will stand-alone or simultaneously enable (i) both purification and determination, (ii) both targeting and imaging and theranostics and (iii) catalysis and determination. The construction and method of preparation is applicable to silica materials, superparamagnetic particles, QDs, CNTs, Ag/Au nanoparticles and Au surfaces and polymeric materials. The photosensitive aminoacid monomer linkers can react via chemically and biocompatible to a lot of different micro and nano-surface and then to the protein when they act as a single-step cross-linking reaction using irradiation.
    Type: Application
    Filed: December 11, 2009
    Publication date: December 22, 2011
    Inventors: Arzu Ersoz, Deniz Hur, Filiz Yilmaz, Adil Denizli, Ayca Atilir Ozcan, Sibel Emir Diltemiz, Suzan Yazar, Ozlem Bicen, Sibel Buyuktiryaki, Rustem Kecili, Guner Saka, Tugba Findik
  • Publication number: 20110306559
    Abstract: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention may comprise a nucleic acid sequence encoding a protein of the invention, which nucleic acid sequence may optionally be provided as a plasmid or within a virus or other vector for delivery to a target cell or tissue. Methods of treating neuropathic pain involving treatment of subject with the compositions of the invention are also provided. Exemplary target genes for the treatment of neuropathic pain include VR1, NaV1.8, and TrkA.
    Type: Application
    Filed: December 23, 2009
    Publication date: December 15, 2011
    Applicant: SANGAMO BIOSCIENCES, INC.
    Inventors: John R.M. Forsayeth, Raymond A. Chavez, Trevor N. Collingwood
  • Patent number: 8058408
    Abstract: Using an undifferentiated mouse CL6 cell line, DMSO was added to induce its differentiation into cardiac muscular cells in order to obtain gene fragments whose expression elevated upon the induction. The isolated gene had zinc finger domains and showed a significant homology to the Sp1 family genes. Furthermore, a human gene corresponding to this mouse gene was isolated. The protein encoded by this gene existed in the nucleus and bonded to a GC-box. The protein was revealed to repress the transcription regulatory activity of the CMV promoter and thus serves as a transcription factor.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: November 15, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Chiaki Senoo, Mariko Numata
  • Publication number: 20110263816
    Abstract: This application provides a metallopeptide catalyst comprising dirhodium bound to one or more carboxylate residues of a peptide, protein or peptidomimetic. These stable metallopeptides can achieve structure-selective protein modification though molecular recognition.
    Type: Application
    Filed: November 23, 2010
    Publication date: October 27, 2011
    Applicant: RICE UNIVERSITY
    Inventors: Zachary Thomas Ball, Brian Vincent Popp, Alexander Nikolaevich Zaykov
  • Publication number: 20110250146
    Abstract: The present invention provides nanoparticles having a core comprising a magnetic material and having a surface, where the surface may be operatively linked to an antigenic peptide-major histocompatibility complex (MHC) monomer. The antigenic peptide-MHC monomer may then be recognized by a T cell receptor. These nanoparticles may further comprise a signal-generating label, such as a fluorophore. Methods employing nanoparticles of the present invention may involve magnetic resonance imaging and/or fluorescence detection, such that cell imaging and localization are performed.
    Type: Application
    Filed: October 8, 2010
    Publication date: October 13, 2011
    Applicants: FRED HUTCHINSON CANCER RESEARCH CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Miqin Zhang, Jonathan Whitney Gunn, Cassian Yee
  • Publication number: 20110251486
    Abstract: A radiolabeled annexin comprising at least 2 up to 20 histidine residues at its N-terminus is disclosed. At least two of said histidine residues are adjacent or separated by no more than one other amino acid. The radiolabeled annexin is a stable complex with a radionuclide such as technetium 99m. The radiolabeled annexin can be used in a method of imaging cell death in a nucleated cell within a region of a mammalian subject in vivo.
    Type: Application
    Filed: August 26, 2009
    Publication date: October 13, 2011
    Inventors: Christiaan Peter Maria Reutelingsperger, Peter Jozef Jacobus Moonen
  • Publication number: 20110250702
    Abstract: The present disclosure relates to peptides isolated from rabbit factor VII and to the use of thereof for the generation of antibodies specifically directed against the latter. The disclosure also relates to the use of antibodies directed against rabbit factor VII for the detection or purification of rabbit factor VII, specifically when said rabbit factor VII is in a biological sample which also contains human factor VII.
    Type: Application
    Filed: December 31, 2009
    Publication date: October 13, 2011
    Applicant: LFB BIOTECHNOLOGIES
    Inventors: Julien Gras, Annick Sauger
  • Publication number: 20110244484
    Abstract: Provided are a method of diagnosing Alzheimer's disease using a giant magnetoresistance sensor and a magnetic bead-polyprotein complex for diagnosing Alzheimer's disease. The method of diagnosing Alzheimer's disease using the giant magnetoresistance sensor may be applied to diagnose Alzheimer's disease more easily and simply using the giant magnetoresistance sensor than using conventional fluorescent materials or genetic analyses, and the magnetic bead-polyprotein complex may be mass-produced as a diagnostic biosensor for Alzheimer's disease, and thus to be useful to monitor and treat Alzheimer's disease.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 6, 2011
    Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Cheol-Joo CHAE, Kwan-Su Kim, Jae-Min Kang, Jeong-Dae Suh, Myung-Ae Chung, Ki-Bong Song
  • Publication number: 20110243849
    Abstract: The present disclosure provides photoactive polypeptides. A subject photoactive polypeptide is useful in a variety of applications, which are also provided.
    Type: Application
    Filed: March 31, 2011
    Publication date: October 6, 2011
    Inventors: Michael A. Marletta, Michael B. Winter, Emily J. McLaurin, Steven Y. Reece, Charles Olea, JR., Daniel G. Nocera
  • Patent number: 8030272
    Abstract: The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: October 4, 2011
    Assignee: Agennix Incorporated
    Inventors: Jose Engelmayer, Atul Varadhachary
  • Publication number: 20110229982
    Abstract: The object of the present invention is to provide a method for immobilizing the SpA protein on the surface of a substrate with high density without causing dimerization. The following method solves the object. That is, the method for binding a protein to a surface of a substrate, comprising steps (A) to (B): step (A) of preparing said protein to the surface, step (B) of supplying said protein to the surface, wherein said protein consists of a Protein A or at least one domain of A to E of said Protein A, and said protein comprises C-terminal modified amino acid sequence represented by SEQ ID:1(SFNRSEC).
    Type: Application
    Filed: March 29, 2011
    Publication date: September 22, 2011
    Applicant: Panasonic Corporation
    Inventors: Jin MURAOKA, Takachika Azuma, Akikazu Murakami
  • Publication number: 20110213046
    Abstract: Nanoparticles can include a core linked to a polymerizable moiety that can be polymerized, cross-linked or cured. The polymerizable nanoparticles can be included in a composition for a polymerization, cross-linking or curing reaction in an amount and disposition sufficient for inhibiting or preventing volume shrinkage during polymerization, cross-linking or curing reaction. Also, the nanoparticles can be included with monomers, dendrimers, oligomers or polymers in the compositions that can be reacted to form a polymerized, cross-linked or cured product.
    Type: Application
    Filed: February 26, 2010
    Publication date: September 1, 2011
    Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventor: Dong Hoon CHOI
  • Patent number: 7994136
    Abstract: A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed.
    Type: Grant
    Filed: May 19, 1989
    Date of Patent: August 9, 2011
    Assignee: Amgen Inc.
    Inventors: Keith E. Langley, Yves A. DeClerck, Thomas C. Boone
  • Publication number: 20110171715
    Abstract: The invention discloses a biocompatible polymer for covalently modifying magnetic nanoparticles. The biocompatible polymer may be coupled to a targeting agent and/or a fluorescent dye. The invention also discloses a magnetic nanoparticle with biocompatibilities comprising the biocompatible polymer.
    Type: Application
    Filed: April 22, 2008
    Publication date: July 14, 2011
    Applicant: Industrial Technology Research Institute
    Inventors: Wen-Hsiang Chang, Wen-Uan Hsieh, Shiu-Hua Huang, Chin-1 Lin, Shian-Jy Jassy Wang, Kelly Teng
  • Publication number: 20110172144
    Abstract: The present invention relates to methods for augmenting SERCA2 mediated calcium ion transport into the sarcoplasmic reticulum of cardiac myocytes of a host. The method includes administering to host cardiac myocytes a zinc finger protein that induces expression of SERCA2a (or administering a nucleic acid molecule encoding such a protein), wherein expression of SERCA2a produces an augmentation in SERCA2 mediated calcium ion transport in treated myocytes, as compared to untreated myocytes. Also provided are methods of treating heart failure by administering to a patient in need thereof, a zinc finger protein or zinc finger protein fused to an effector domain, that induces expression of SERCA2a.
    Type: Application
    Filed: January 4, 2011
    Publication date: July 14, 2011
    Applicant: CELLADON CORPORATION
    Inventor: Krisztina M. Zsebo
  • Publication number: 20110142762
    Abstract: This invention relates to the delivery of agents to the body. One particular class of such agents are contrast agents useful in medical imaging techniques. The agents may be metals useful as contrast agents in magnetic resonance imaging (MRI), or in nuclear imaging, including positron emission tomography (PET), or as therapeutic agents in radiotherapy. The agents may alternatively be contrast agents useful in X-ray imaging. The invention also relates to methods by which agents for delivery to the body can be coupled to carriers and to targeting moieties effective to direct the agent to a specific locus within the body.
    Type: Application
    Filed: January 19, 2011
    Publication date: June 16, 2011
    Applicants: Novozymes Biopharma DK A/S, Upperton Limited
    Inventor: John Rodney Woodrow
  • Publication number: 20110130550
    Abstract: A protein polymer having a larger molecular weight is provided by regularly arranging a protein having a large molecular weight. The protein polymer having a large molecular weight can be obtained using a protein monomer represented by formula (I) or a salt thereof: wherein R1, R2, R3, R4, Y, and X are as defined in the specification.
    Type: Application
    Filed: March 10, 2009
    Publication date: June 2, 2011
    Applicant: OSAKA UNIVERSITY
    Inventors: Takashi Hayashi, Hiroaki Kitagishi, Koji Oohora, Akira Onoda, Yasuaki Kakikura
  • Publication number: 20110118449
    Abstract: Ferritin 2 is a tick secreted protein, which serves in the tick plasma as a non-heme iron transporter from the gut to the peripheral tissues. It can be exploited as an antigen for raising up host antibodies, which can reversely block this antigen in the tick and the attached tick will not have functional mechanism of the non-heme iron transport from the gut to the peripheral tissues. This mechanism is essential for the further tick development and its blocking eventually prevents transmission of tick-borne pathogens.
    Type: Application
    Filed: June 18, 2009
    Publication date: May 19, 2011
    Inventors: Petr Kopacek, Ondrej Hajdusek
  • Publication number: 20110110866
    Abstract: A magnetic resonance imaging (MRI) contrast enhancement agent comprising an elastin-like polypeptide (ELP) and one or more paramagnetic metal ions is disclosed. Also disclosed are methods of preparing ELP MRI contrast enhancement agents, formulations comprising ELP MRI contrast enhancement agents, and methods of using ELP MRI contrast enhancement agents to image biological samples and to image and deliver therapeutic agents to targeted sites in vivo. In some embodiments, the ELP MRI agents can be used in methods related to blood volume determination, in magnetic resonance angiography (MRA), and in vascular transport determinations. The ELP MRI contrast agents can also provide information on the expression of various proteins through affinity targeting or enzymatic crosslinking in order to aid in diagnosis and in the spatial definition of pathologic tissue.
    Type: Application
    Filed: April 10, 2008
    Publication date: May 12, 2011
    Applicant: Duke University
    Inventors: Ashutosh Chilkoti, Matthew R. Dreher, Daniel E. Meyer, Mark W. Dewhirst
  • Publication number: 20110111422
    Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.
    Type: Application
    Filed: September 1, 2010
    Publication date: May 12, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Kurt VOGEL, Rhonda Newman, Steven Riddle
  • Publication number: 20110104103
    Abstract: The present invention relates to a cell-targeting complex comprising a targeting moiety and a deliverable compound, wherein said targeting moiety and said deliverable compound are joined by means of a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said deliverable compound, and wherein said deliverable compound is a therapeutic compound.
    Type: Application
    Filed: July 20, 2006
    Publication date: May 5, 2011
    Applicant: KREATECH BIOTECHNOLOGY B.V.
    Inventors: Robert Jochem Heetebrij, Robbert Jan Kok, Eduard Gerhard Talman, Klaas Poelstra, Grietje Molema
  • Publication number: 20110098211
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Application
    Filed: January 29, 2009
    Publication date: April 28, 2011
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
  • Publication number: 20110097742
    Abstract: Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like.
    Type: Application
    Filed: April 2, 2009
    Publication date: April 28, 2011
    Inventors: Jenny Jie Yang, Zhiren Liu, Shunyi Li, Yubin Zhou, Jie Jiang, Shenghui Xue, Jinjuan Qiao, Lixia Wei
  • Publication number: 20110092434
    Abstract: The present invention relates to the use of at least one compound comprising the amino acid sequence: (X1)nX2X3PVX4X5X6(X7)m (Formula I), wherein X1 is any amino acid residue, X2 is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E).
    Type: Application
    Filed: February 23, 2009
    Publication date: April 21, 2011
    Applicant: AFFIRIS AG
    Inventors: Markus Mandler, Harald Weninger, Radmila Santic, Edith Kopinits
  • Publication number: 20110082093
    Abstract: Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.
    Type: Application
    Filed: July 28, 2010
    Publication date: April 7, 2011
    Inventors: PHILIP D. GREGORY, EDWARD J. REBAR, H. STEVE ZHANG
  • Publication number: 20110082078
    Abstract: Disclosed herein are methods and compositions for treating neuropathies by modulating endogenous NT-3 of GDNF gene expression.
    Type: Application
    Filed: February 4, 2010
    Publication date: April 7, 2011
    Inventors: Carolyn Dent, Josee Laganiere, Xiangdong Meng, David Paschon, Siyuan Tan, Lei Zhang, Steve H. Zhang
  • Patent number: 7919596
    Abstract: To provide a method of arranging ferritin by which a high rate of the number of the molecular film spots on which sole ferritin molecule was arranged in effect, with respect to total number of the molecular film spots provided for arranging ferritin (sole arrangement rate) is achieved is objected to. Specifically, in Fer8 ferritin having a sequence excluding 7 amino acids of from the second to the eighth, from an amino acid sequence (Fer0 sequence) translated from a naturally occurring DNA sequence, lysine at position 91 is substituted with glutamic acid.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: April 5, 2011
    Assignee: Panasonic Corporation
    Inventors: Shigeo Yoshii, Kazuaki Nishio, Shinya Kumagai, Ichiro Yamashita
  • Publication number: 20110076264
    Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 31, 2011
    Inventors: Robert Jordan, David Knight, Randall Brezski
  • Publication number: 20110053292
    Abstract: There is provided a novel method for amplifying mass spectrometric signals. More particularly, a novel method for detecting signals of a target molecule includes: i) allowing a test sample, in which it is required to determine whether or not a target molecule is present, to be contact with a gold particle whose surface is modified to selectively bind to the target molecule, ii) allowing a low molecular molecule engrafted to the gold particle to generate mass spectrometric signals after the interaction, such as binding, between the gold particle and the target molecule, and iii) amplifying the mass spectrometric signals by generating a great deal of mass spectrometric signals of the low molecular molecule even in the presence of a trace of the target molecule. Also, the assay system using the method and the gold particle prepared in the method are provided.
    Type: Application
    Filed: April 10, 2009
    Publication date: March 3, 2011
    Applicant: PROBIOND CO., LTD.
    Inventors: Hyung-Soon Park, Sang-Wan So, Woon-Seok Yeo, Soo-Jae Lee, Jung-Rok Lee, Ju-Hee Lee, Kwang-Pyo Kim
  • Patent number: 7893024
    Abstract: The present invention provides methods of enhancing the rate of iron release from ferritin. By increasing the amount of iron available for chelation, the invention also provides methods of treating conditions associated with iron overload. The invention also provides in one embodiment agents which are useful for treating iron overload.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: February 22, 2011
    Assignee: Children's Hospital & Research Center at Oakland
    Inventor: Elizabeth Theil
  • Publication number: 20110038798
    Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumours following cancer treatment.
    Type: Application
    Filed: April 29, 2009
    Publication date: February 17, 2011
    Applicant: Cambridge Enterprise Limited
    Inventors: Kevin Brindle, Andre Neves, Maaike De Backer, Israt Alam
  • Publication number: 20110015344
    Abstract: Degradable complexes comprising a polycation, a polyanion and a polynucleotide are useful for in vivo polynucleotide delivery applications.
    Type: Application
    Filed: September 10, 2010
    Publication date: January 20, 2011
    Applicant: NITTO DENKO CORPORATION
    Inventors: Sang Van, Jiadong Zhou, Xiaoli Fu, Lei Yu
  • Publication number: 20110014675
    Abstract: Polynucleotides encoding chimeric proteins, and methods for their production and use are disclosed. The chimeric proteins comprise a flexible linker between two zinc finger DNA-binding domains, wherein the linker contains eight or more amino acids between the second conserved histidine residue of the carboxy-terminal zinc finger of the first domain and the first conserved cysteine residue of the amino-terminal zinc finger of the second domain.
    Type: Application
    Filed: August 13, 2009
    Publication date: January 20, 2011
    Applicant: Massachusetts Institute of Technology
    Inventors: Jin-Soo Kim, Carl O. Pabo
  • Publication number: 20110014710
    Abstract: Methods, compositions, and kits for labeling tetracysteine-tagged proteins with biarsenical fluorophores with increased specificity, including compositions, methods and kits particularly adapted for labeling of tetracysteine-tagged proteins to be resolved within an electrophoresis gel.
    Type: Application
    Filed: July 28, 2009
    Publication date: January 20, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Roumen A. Bogoev, Joseph W. Amshey, George Hanson
  • Publication number: 20100329995
    Abstract: The present invention relates, generally, to compositions including lactoferrin, and to compositions including both lactoferrin and lysozyme. The present invention also includes topical formulations containing the compositions, methods of making the formulations, methods of using the formulations to treat various skin disorders/conditions, to treat wounds, and to methods of producing artificial skin using the composition, and methods of treating burns using the formulation, optionally in conjunction with the application of artificial skin.
    Type: Application
    Filed: February 21, 2007
    Publication date: December 30, 2010
    Applicant: VENTRIA BIOSCIENCE
    Inventors: Scott E. Deeter, Delia R. Bethell, Brandy Sargent
  • Patent number: 7834160
    Abstract: An object of the present invention is to obtain a zinc oxide-protein complex which can be a source of nanoparticles of zinc oxide utilizing a protein having a cavity inside thereof. The process for producing a zinc oxide-protein complex according to the present invention includes a hydrogen peroxide addition step for adding hydrogen peroxide so that the concentration would be 60 mM or greater and 150 mM or less to a buffer containing a protein having a cavity inside thereof such as ferritin, zinc ion, and ammonia.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: November 16, 2010
    Assignee: Panasonic Corporation
    Inventors: Mitsuhiro Okuda, Kazuaki Nishio, Ichiro Yamashita
  • Publication number: 20100284909
    Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Application
    Filed: May 5, 2010
    Publication date: November 11, 2010
    Applicant: NEW YORK UNIVERSITY
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Publication number: 20100282670
    Abstract: There is provided a metal recovery device 10 for removing and recovering predetermined metal, from a liquid to be processed, by passing the liquid to be processed through a filter 41, wherein a constituent material of the filter 41 contains a protein that absorbs iron, radium, or heavy metal (except iron).
    Type: Application
    Filed: May 5, 2010
    Publication date: November 11, 2010
    Inventor: Eizo NAKAMURA
  • Publication number: 20100279432
    Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.
    Type: Application
    Filed: July 8, 2010
    Publication date: November 4, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
  • Publication number: 20100273981
    Abstract: The invention concerns the application of silintaphin-1 in the sustainable fabrication of hierarchically ordered silica structures from nano- to macro-scale at environmentally benign conditions and low energy costs (low temperature, low pressure, absence of caustic chemicals).
    Type: Application
    Filed: April 27, 2010
    Publication date: October 28, 2010
    Inventors: Matthias WIENS, Werner E.G. Müller, Heinz C. Schröder, Xiaohong Wang
  • Publication number: 20100267056
    Abstract: The invention relates to a method for differentially labelling one or more entities, together comprising distinct reactive sites. The invention further relates to an entity that has been labelled by a method according to the invention and to a diagnostic kit comprising a labelled entity and to a diagnostic kit to employ a method according to the invention.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 21, 2010
    Applicant: KREATECH BIOTECHNOLOGY B.V.
    Inventors: Eduard Gerhard Talman, Robertus Petrus Maria van Gijlswijk, Robert Jochem Heetebrij, Jacky Theo Maria Veuskens
  • Patent number: RE42211
    Abstract: Disclosed are libraries of DNA sequences encoding zinc finger binding motifs for display on a particle, together with methods of designing zinc finger binding polypeptides for binding to a particular target sequence and, inter alia, use of designed zinc finger polypeptides for various in vitro or in vivo applications.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: March 8, 2011
    Assignee: Gendaq, Limited
    Inventors: Yen Choo, Aaron Klug, Isidro Sanchez-Garcia